BOARD OF DIRECTORS:
Oren Gilad, Ph.D – President and CEO
A researcher, scientific entrepreneur and innovator, Dr. Gilad has extensive hands-on experience across early phases of drug research and development. Over the course of a 13-year academic career, he has authored several high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research, which was conducted at the University of Pennsylvania, led to Dr. Gilad co-founding Atrin Pharmaceuticals in 2011. This is the third company that he has set up, the first two having been sold.
Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D and post-doctorate from University of California at Davis, and a post-doctorate from the University of Pennsylvania.
Mr. Rudnick has over 35 years of experience in executive-level strategy, finance, and management, including in biotech companies. He co-founded multiple companies, including CapGenic Advisors, LLC, and a number of start-ups, three of which grew to over $60 million in revenue before exiting. He is also a founder of one of the US’s leading entrepreneurial programs (MADV) at the Fox School of Business in Philadelphia. Working with businesses ranging from start-ups to Fortune 50 companies, Mr. Rudnick has developed extensive experience in senior merger, acquisition, capital formation and licensing leadership. He also has substantial experience investing and guiding investments in entrepreneurial companies, and has led capital formation totaling more than $3 billion over the last 15 years. Mr. Rudnick is affiliated with several angel groups, including Minority Angel Investment Network, Mid-Atlantic Bio Angels (which he co-founded) and Keiretsu Mid-Atlantic.
Rifat Pamucku, M.D. - Chief Medical Advisor
Dr. Pamukcu has extensive experience in pharmaceuticals and drug development, with a particular focus on oncology. He currently serves as the President and CEO of Midway Pharmaceuticals. He was also a co-founder, Director and CSO of Cell Pathways (NASDAQ:CLPA, acquired by OSI Pharmaceuticals), where he directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing, and raised over $140 million of investment capital. Dr. Pamukcu has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems. He is an inventor on over 280 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention, cancer chemotherapeutics and inflammatory bowel disease.
Michael Grissinger, MBA
Michael Grissinger spent 22 years at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He has led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger brings to Atrin extensive experience in business and corporate development, finance, marketing and strategic planning in the pharmaceutical industry. Prior to joining Johnson & Johnson, Mr. Grissinger spent 20 years in the healthcare industry with Ciba-Geigy and SmithKline Beckman.
Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
Jeffrey Dayno, M.D.
Dr. Dayno is currently the Chief Medical Officer of Egalet. He spent ten years in clinical and academic medicine before moving into the pharmaceutical industry. He previously served as Vice President, Global Medical Affairs at ViroPharma, Chief Medical Officer at Labopharm, Inc., and Vice President of Medical Affairs at Cephalon, Inc. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent seven years in positions of increasing responsibility in the medical and scientific affairs divisions.
Before moving into leadership roles in the pharmaceutical and biotechnology industry, Dr. Dayno held a number of clinical appointments, including Assistant Professor of Neurology, Jefferson Medical College, and Medical Director of the Jefferson Health System Stroke Center Network. Dr. Dayno is currently a member of the Board of Visitors of Temple University School of Medicine, and is a former Chairman of the Philadelphia Stroke Council.
Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health (NIH) Clinical Research Center for stroke and headache, and was board certified in neurology.
Dr. Jay Rosan
Dr. Rosan is a former Vice President of Health Innovation for Walgreens, and Senior VP of Health Innovation at the Walgreens Health and Wellness Division. Dr. Rosan was one of the first medical directors at HMO of Pennsylvania, which grew to become US Healthcare, and while there held many senior corporate leadership positions and developed one of the first and largest breast and colorectal cancer screening programs in the United States. He is a member of Robin Hood Ventures, an angel group that provides both financial and mentoring help to startup companies in the Delaware Valley. Dr. Rosan is a family physician and serial entrepreneur with over 30 years’ experience in extensive leadership experience in various industries, most prominently those related to medicine and health insurance.
Marc Duey, M.Sc, MBA
Mr. Duey is the Founder, President and CEO of ProMetrics Inc. He has over three decades of experience in the Pharmaceutical and Biotechnology industries and brings a great deal of commercial business experience to Atrin. Mr. Duey founded ProMetrics to provide marketing and sales teams with strategic database and decision support services for dynamic healthcare manufacturers and innovative service firms. Under his direction, the firm has helped launch dozens of biopharma products, serviced over 130 clients, and managed over 6,200 projects. Prior to founding ProMetrics, Mr. Duey was founder and President of DuWest Research, an international management consulting firm, with offices on three continents, that specialized in serving the needs of diagnostic and biotechnology firms. Mr. Duey is a member of numerous trade and industry associations and sits on the Board of Directors of several technology companies. He is an adjunct professor at West Chester University in both the Graduate Business School (MBA) and the Pharmaceutical Product Development program (PPD).
Mr. Capocasale is the Founder and CEO of FlowMetric, Inc., a niche Contract Research Organization (CRO) established in early 2010, and has over 20 years of experience in pharmaceutical research and development. He is an expert in polychromatic flow cytometry, cell sorting and immunology-based assay development. Prior to establishing FlowMetric, Mr. Capocasale worked for over 13 years at Centocor, a subsidiary of Johnson and Johnson. His work at Centocor earned him five prestigious Johnson & Johnson awards for scientific excellence and innovation.
Mr. Capocasale has authored more than 30 peer reviewed scientific manuscripts and publications. He sits on the Board of Trustees of Neumann University, and is also a board member of iPraxis, a not-for-profit educational institution focused on science and technology education. Mr. Capocasale is an Adjunct Professor at Drexel University College of Medicine.
Mr. Capocasale earned his undergraduate degree from Villanova University.